Mesoblast (MESO) EBIT (2015 - 2023)

Mesoblast (MESO) has 9 years of EBIT data on file, last reported at -$117.9 million in Q2 2023.

• For the quarter ending Q2 2023, EBIT rose 15.84% year-over-year to -$117.9 million; the trailing twelve-month figure through Jun 2023 stood at -$63.0 million (up 23.64% YoY), and the FY2025 full-year result was -$62.0 million, up 4.09% from the prior year.
• EBIT fell to -$117.9 million in Q2 2023, from $13.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $22.0 million in Q4 2021 to a low of -$140.1 million in Q2 2022.
• A 5-year average of -$19.9 million and a median of -$19.1 million in 2020 frame the typical range for EBIT.
• Across the five-year window, EBIT surged 181.34% in 2021 and sank 1821.53% in 2022, its largest moves.
• Tracing MESO's EBIT over 5 years: stood at -$29.4 million in 2019, then advanced by 8.15% to -$27.0 million in 2020, then jumped by 181.34% to $22.0 million in 2021, then dropped by 10.51% to $19.7 million in 2022, then sank by 699.79% to -$117.9 million in 2023.
• Business Quant data shows MESO's EBIT at -$117.9 million in Q2 2023, $13.7 million in Q1 2023, and $19.7 million in Q4 2022.